$1.72
2.27% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

ESSA Pharma Inc Stock price

$1.72
-4.23 71.09% 1M
-4.48 72.26% 6M
-4.88 73.94% YTD
-3.53 67.24% 1Y
-11.27 86.76% 3Y
-3.43 66.60% 5Y
-86.59 98.05% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.04 2.27%
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

Key metrics

Market capitalization $76.31m
Enterprise Value $-54.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.28
P/B ratio (TTM) P/B ratio 0.59
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-33.88m
Free Cash Flow (TTM) Free Cash Flow $-23.75m
Cash position $130.69m
EPS (TTM) EPS $-0.63
P/E forward negative
Short interest 4.30%
Show more

Is ESSA Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

ESSA Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ESSA Pharma Inc forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a ESSA Pharma Inc forecast:

Hold
100%

Financial data from ESSA Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.10 0.10
17% 17%
-
-0.10 -0.10
17% 17%
-
- Selling and Administrative Expenses 11 11
0% 0%
-
- Research and Development Expense 22 22
9% 9%
-
-34 -34
6% 6%
-
- Depreciation and Amortization 0.10 0.10
17% 17%
-
EBIT (Operating Income) EBIT -34 -34
6% 6%
-
Net Profit -28 -28
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about ESSA Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ESSA Pharma Inc Stock News

Neutral
PRNewsWire
15 days ago
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens  A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar ...
Neutral
PRNewsWire
2 months ago
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA
Neutral
PRNewsWire
2 months ago
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
More ESSA Pharma Inc News

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Head office Canada
CEO David Parkinson
Employees 50
Founded 2009
Website www.essapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today